2007 Annual Meeting | Management of Common Behavioral Disturbances in Dementia
| 06:15 PM - 09:30 PM |
Dinner
|
|
| 06:30 PM - 06:40 PM |
Introduction
Kimford J. Meador, MD, FAAN |
|
| 06:40 PM - 07:30 PM |
Behavioral Effects of Antidementia Agents
Jeffrey L. Cummings, MD, FAAN |
|
| 07:30 PM - 08:20 PM |
Psychotropics and Dementia
David Geldmacher, MD |
|
| 08:20 PM - 09:10 PM |
Case Studies
Kimford J. Meador, MD, FAAN |
|
| 09:10 PM - 09:30 PM |
Questions and Answers
|
| Jeffrey L. Cummings, MD, FAAN | Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care. |
| Kimford J. Meador, MD, FAAN | The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from Eisai. The institution of Dr. Meador has received research support from Medtronics. The institution of Dr. Meador has received research support from The Epilepsy Consortium. |
| David Geldmacher, MD | Dr. Geldmacher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Geldmacher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lilly. Dr. Geldmacher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Geldmacher has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for BrownGreer. Dr. Geldmacher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Penn Partners. Dr. Geldmacher has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oligomerix. Dr. Geldmacher has stock in Doximity. The institution of Dr. Geldmacher has received research support from Biogen. The institution of Dr. Geldmacher has received research support from Eisai. The institution of Dr. Geldmacher has received research support from Janssen. The institution of Dr. Geldmacher has received research support from National Institutes of Health. The institution of Dr. Geldmacher has received research support from Vaccinex. Dr. Geldmacher has received personal compensation in the range of $500-$4,999 for serving as a CME presenter with Medscape. Dr. Geldmacher has received personal compensation in the range of $10,000-$49,999 for serving as a CME presenter with Med Learning Group. Dr. Geldmacher has received personal compensation in the range of $5,000-$9,999 for serving as a CME presenter/committee member with HMP . Dr. Geldmacher has received personal compensation in the range of $5,000-$9,999 for serving as a CME program development/presenter with CME Institute. |